The European Medicines Agency (EMA) and the European Organisation for Research and Treatment of Cancer (EORTC) are jointly organising a workshop on how patient-reported outcomes (PRO) as well as health-related quality of life (HRQoL) data can inform regulatory decisions (please see the draft agenda attached).

This workshop will bring together international experts from academia, learned societies, patients, regulatory agencies, health technology assessment bodies, and industry.  The aims of the workshop are to:

Participants can register to the workshop by completing the following registration form:

 Registration will close on 15th January 2024 for in-person participation and will remain open until 16th February 2024 for online participation.

 Please note that in-person participation will be subject to confirmation by 22nd January 2024 to ensure equal input from all stakeholders and taking into consideration the capacity of the venue.

 The recording of this meeting will be made available after the event.